TMED6 (transmembrane p24 trafficking protein 6) is a transmembrane protein localized to the endoplasmic reticulum and Golgi apparatus that functions in intracellular vesicular transport, particularly in COPII-coated ER to Golgi transport 1. In normal physiology, TMED6 is expressed in pancreatic β cells and influences glucose-stimulated insulin secretion; siRNA knockdown of TMED6 in INS1 cells reduced glucose-stimulated insulin secretion 2, suggesting a role in glucose metabolism. Mechanistically, TMED6 expression is upregulated downstream of the transcription factor Mist1 in response to oxidative stress, enhancing ROS resistance in gastric cells 3. Genetically, TMED6 has been identified as a pleiotropic locus associated with both leukocyte telomere length and coronary artery disease risk 4. Clinically, TMED6 is notable as a molecular marker for TFE3 translocation renal cell carcinoma; the TMED6-COG8 chimeric transcript is dramatically elevated in this aggressive malignancy and can serve as a diagnostic indicator 56. Additionally, TMED6 is implicated in colorectal cancer genomic instability and has been proposed as a potential therapeutic target 7. Recent advances have developed RNA aptamers targeting TMED6 for β cell-specific delivery of imaging agents and therapeutics, demonstrating potential clinical applications in diabetes treatment 1.